Key facts
- Alume Biosciences’s last known valuation is $127.8M (Jan 2023).
- It has raised $31.2M across 6 recorded rounds; the latest was Seed Round ($2.2M) in Mar 2026.
- Notable investors include University of California, Johnson & Johnson Innovation - JLABS, ALMA Life Sciences, Biobrit, Chrysa Mineo — 10 tracked in total.
- Alume Biosciences has filed 7 Form Ds with the SEC since 2019, most recently May 2026 ($2.2M sold to 4 investors).
- Status: Privately Held (backing).
Investors
10- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Alume Biosciences
Funding rounds
6 roundsAbout Alume Biosciences
Developer of a nerve illumination technology designed to help doctors perform precision surgery. The company's technology illuminates nerves during surgery, making them visible to the surgical team, enabling surgeons to prevent nerve damage while performing complex organ surgeries.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2017
- Employees
- 11
- Website
- alumebiosciences.com/
- Ownership
- Privately Held (backing)
Alume Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alume Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alume Biosciences in its N-PORT filings yet. We sweep new filings monthly.